Title: PROBIOTIC LACTOBACILLUS CASEI STRAINS

Abstract: A Lactobacillus casei strain or a mutant or variant thereof isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. In particular a Lactobacillus casei strain, AH101, AH104, AH111, AH112 or AH113 or mutants or variants are thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
"Probiotic Lactobacillus casei strains"

Introduction

The invention relates to Lactobacillus casei strains and their use as probiotic bacteria in particular as immunomodulatory biotherapeutic agents.

The defense mechanisms to protect the human gastrointestinal tract from colonization by intestinal bacteria are highly complex and involve both immunological and non-immunological aspects (1). Innate defense mechanisms include the low pH of the stomach, bile salts, peristalsis, mucin layers and anti-microbial compounds such as lysozyme (2). Immunological mechanisms include specialized lymphoid aggregates, underlying M cells, called peyers patches which are distributed throughout the small intestine and colon (3). Luminal antigens presented at these sites result in stimulation of appropriate T and B cell subsets with establishment of cytokine networks and secretion of antibodies into the gastrointestinal tract (4). In addition, antigen presentation may occur via epithelial cells to intraepithelial lymphocytes and to the underlying lamina propria immune cells (5). Therefore, the host invests substantially in immunological defense of the gastrointestinal tract. However, as the gastrointestinal mucosa is the largest surface at which the host interacts with the external environment, specific control mechanisms must be in place to regulate immune responsiveness to the 100 tons of food which is handled by the gastrointestinal tract over an average lifetime. Furthermore, the gut is colonized by over 500 species of bacteria numbering $10^{11}$-$10^{12}$/g in the colon. Thus, these control mechanisms must be capable of distinguishing non-pathogenic adherent bacteria from invasive pathogens, which would cause significant damage to the host. In fact, the intestinal flora contributes to defense of the host by competing with newly ingested potentially pathogenic micro-organisms.

Bacteria present in the human gastrointestinal tract can promote inflammation. Aberrant immune responses to the indigenous microflora have been implicated in
certain disease states, such as inflammatory bowel disease. Antigens associated with the normal flora usually lead to immunological tolerance and failure to achieve this tolerance is a major mechanism of mucosal inflammation (6). Evidence for this breakdown in tolerance includes an increase in antibody levels directed against the gut flora in patients with IBD.

The present invention is directed towards *Lactobacillus* strains, which have been shown to have immunomodulatory effects, by modulating cytokine levels or by antagonizing and excluding pro-inflammatory micro-organisms from the gastrointestinal tract.

**Statements of Invention**

According to the invention there is provided a *Lactobacillus casei* strain or a mutant or variant thereof isolated from resected and washed human gastrointestinal tract. The invention also provides a *Lactobacillus casei* strain or a mutant or variant thereof, wherein the *Lactobacillus casei* strain is significantly immunomodulatory following oral consumption in humans.

According to the invention there is provided a *Lactobacillus casei* strain selected from any one or more of AH101, AH104, AH111, AH112 and AH113 or a mutant or variant thereof.

The mutant may be a genetically modified mutant. The variant may be a naturally occurring variant of *Lactobacillus casei*.

In one embodiment of the invention *Lactobacillus casei* strain is in the form of viable cells. Alternatively *Lactobacillus* strains are in the form of non-viable cells.

In one embodiment of the invention the *Lactobacillus casei* strains are in the form of a biologically pure culture.
In one embodiment of the invention the *Lactobacillus casei* is isolated from resected and washed human gastrointestinal tract. Preferably the *Lactobacillus casei* strains are significantly immunomodulatory following oral consumption in humans.

The invention also provides a formulation which comprises at least one *Lactobacillus casei* strain of the invention. The formulation may comprise two or more strains of *Lactobacillus*.

In one embodiment of the invention the formulation includes another probiotic material.

In one embodiment of the invention the formulation includes a prebiotic material.

Preferably the formulation includes an ingestable carrier. The ingestable carrier may be a pharmaceutically acceptable carrier such as a capsule, tablet or powder. Preferably the ingestable carrier is a food product such as acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spreads, dressings or beverages.

In one embodiment of the invention the formulation of the invention further comprises a protein and/or peptide, in particular proteins and/or peptides that are rich in glutamine/glutamate, a lipid, a carbohydrate, a vitamin, mineral and/or trace element.

In one embodiment of the invention *Lactobacillus casei* strains are present in the formulation at more than $10^6$ cfu per gram of delivery system. Preferably the formulation includes any one or more of an adjuvant, a bacterial component, a drug entity or a biological compound.

In one embodiment of the invention the formulation is for immunisation and vaccination protocols.
The invention further provides *Lactobacillus casei* strains or a formulation of the invention for use as foodstuffs, as a medicament, for use in the prophylaxis and/or treatment of undesirable inflammatory activity, for use in the prophylaxis and/or treatment of undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease eg. Crohn's disease or ulcerative colitis, irritable bowel syndrome, pouchitis, or post infection colitis, for use in the prophylaxis and/or treatment of gastrointestinal cancer(s), for use in the prophylaxis and/or treatment of systemic disease such as rheumatoid arthritis, for use in the prophylaxis and/or treatment of autoimmune disorders due to undesirable inflammatory activity, for use in the prophylaxis and/or treatment of cancer due to undesirable inflammatory activity, for use in the prophylaxis of cancer, for use in the prophylaxis and/or treatment of diarrhoeal disease due to undesirable inflammatory activity, such as *Clostridium difficile* associated diarrhoea, Rotavirus associated diarrhoea or post infective diarrhoea, for use in the prophylaxis and/or treatment of diarrhoeal disease due to an infectious agent, such as *E.coli*.

The invention also provides *Lactobacillus casei* strains or a formulation of the invention for use in the preparation of an anti-inflammatory biotherapeutic agent for the prophylaxis and/or treatment of undesirable inflammatory activity or for use in the preparation of anti-inflammatory biotherapeutic agents for the prophylaxis and/or treatment of undesirable inflammatory activity.

In one embodiment of the invention the strains of the invention act by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract.

The invention also provides *Lactobacillus casei* strains or a formulation of the invention for use in the preparation of anti-inflammatory biotherapeutic agents for reducing the levels of pro inflammatory cytokines.
The invention further provides *Lactobacillus casei* AH111 for use in the preparation of anti-inflammatory biotherapeutic agents for reducing the levels of IL-8.

The invention further provides *Lactobacillus casei* strains use in the preparation of anti-inflammatory biotherapeutic agents for modifying the levels of IL-8, IL-10, IL-12, TNFα or IFNγ.

The invention further provides *Lactobacillus casei* strains for use in the preparation of anti-inflammatory biotherapeutic agents for modifying the levels of IFNγ. Preferably in this case the strains are selected from any one of AH101, AH104, AH112 or AH113.

The invention also provides for the use of anti-infective probiotic strains due to their ability to antagonise the growth of pathogenic species.

We have found that particular strains of *Lactobacillus casei* elicit immunomodulatory effects *in vitro*.

The invention is therefore of major potential therapeutic value in the prophylaxis or treatment of dysregulated immune responses, such as undesirable inflammatory reactions, for example inflammatory bowel disease.

The strains may be used as a panel of biotherapeutic agents from which a selection can be made for modifying the levels of IFNγ, TNFα, IL-8, IL-10 and/or IL-12.

The strains or formulations of the invention may be used in the prevention and/or treatment of inflammatory disorders, immunodeficiency, inflammatory bowel disease, irritable bowel syndrome, cancer (particularly of the gastrointestinal and immune systems), diarrhoeal disease, antibiotic associated diarrhoea, paediatric diarrhoea, appendicitis, autoimmune disorders, multiple sclerosis, Alzheimer's disease, rheumatoid arthritis, coeliac disease, diabetes mellitus, organ transplantation, bacterial
infections, viral infections, fungal infections, periodontal disease, urogenital disease, sexually transmitted disease, HIV infection, HIV replication, HIV associated diarrhoea, surgical associated trauma, surgical-induced metastatic disease, sepsis, weight loss, anorexia, fever control, cachexia, wound healing, ulcers, gut barrier function, allergy, asthma, respiratory disorders, circulatory disorders, coronary heart disease, anaemia, disorders of the blood coagulation system, renal disease, disorders of the central nervous system, hepatic disease, ischaemia, nutritional disorders, osteoporosis, endocrine disorders, epidermal disorders, psoriasis and/or acne vulgaris.

The *Lactobacillus* strains are commensal microorganisms. They have been isolated from the microbial flora within the human gastrointestinal tract. The immune system within the gastrointestinal tract cannot have a pronounced reaction to members of this flora, as the resulting inflammatory activity would also destroy host cells and tissue function. Therefore, some mechanism(s) exist whereby the immune system can recognize commensal non-pathogenic members of the gastrointestinal flora as being different to pathogenic organisms. This ensures that damage to host tissues is restricted and a defensive barrier is still maintained.

A deposit of *Lactobacillus casei* strain AH101 was made at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) on April 20, 2000 and accorded the accession number NCIMB 41043.

A deposit of *Lactobacillus casei* strain AH104 was made at the NCIMB on April 20, 2000 and accorded the accession number NCIMB 41046.

A deposit of *Lactobacillus casei* strain AH111 was made at the NCIMB on March 22, 2001 and accorded the accession number NCIMB 41095.

A deposit of *Lactobacillus casei* strain AH112 was made at the NCIMB on March 22, 2001 and accorded the accession number NCIMB 41096.
A deposit of *Lactobacillus casei* strain AH113 was made at the NCIMB on March 22, 2001 and accorded the accession number NCIMB 41097.

The *Lactobacillus casei* may be a genetically modified mutant or it may be a naturally occurring variant thereof.

Preferably the *Lactobacillus casei* is in the form of viable cells. Alternatively the *Lactobacillus casei* may be in the form of non-viable cells.

It will be appreciated that the specific Lactobacillus strain of the invention may be administered to animals (including humans) in an orally ingestible form in a conventional preparation such as capsules, microcapsules, tablets, granules, powder, troches, pills, suppositories, suspensions and syrups. Suitable formulations may be prepared by methods commonly employed using conventional organic and inorganic additives. The amount of active ingredient in the medical composition may be at a level that will exercise the desired therapeutic effect.

The formulation may also include a bacterial component, a drug entity or a biological compound.

In addition a vaccine comprising the strain of the invention may be prepared using any suitable known method and may include a pharmaceutically acceptable carrier or adjuvant.

Throughout the specification the terms mutant, variant and genetically modified mutant include a strain of *Lactobacillus salivarius* whose genetic and/or phenotypic properties are altered compared to the parent strain. Naturally occurring variant of *Lactobacillus casei* includes the spontaneous alterations of targeted properties selectively isolated while deliberate alteration of parent strain properties may be accomplished by conventional genetic manipulation technologies, such as gene disruption, conjugative transfer, etc.
Brief description of the drawings

Fig. 1 is a bar graph showing the adhesive nature of *Lactobacillus casei* strains to human gastrointestinal epithelial cells, CaCo –2 and HT –29;

Fig. 2 is a bar graph showing the stimulatory effect on IFNγ production (pg/ml) by PBMCs following co-incubation with *Lactobacillus casei* strains;

Fig. 3 is a bar graph showing the immunomodulatory nature of *Lactobacillus casei* strains on the production of IL-10 (pg/ml) by PBMCs;

Fig. 4 is a bar graph showing IL-12 production (pg/ml) after incubation with *Lactobacillus casei* strains;

Fig. 5 is a bar graph showing IL-8 production (pg/ml) after incubation with AH111 and AH112; and

Fig. 6 is a bar graph showing TNFα production (pg/ml) after incubation with AH112.

Detailed Description

We have found that *Lactobacillus casei* AH101, AH104, AH111, AH112 and AH113 are not only acid and bile tolerant and adhere to human intestinal cell lines but also, surprisingly have immunomodulatory effects, by modulating cytokine levels or by antagonising and excluding pro-inflammatory or immunomodulatory micro-organisms from the gastrointestinal tract.
The general use of probiotic bacteria is in the form of viable cells. However, it can also be extended to non-viable cells such as killed cultures or compositions containing beneficial factors expressed by the probiotic bacteria. This could include thermally killed micro-organisms or micro-organisms killed by exposure to altered pH or subjection to pressure. With non-viable cells product preparation is simpler, cells may be incorporated easily into pharmaceuticals and storage requirements are much less limited than viable cells. *Lactobacillus casei* YIT 9018 offers an example of the effective use of heat killed cells as a method for the treatment and/or prevention of tumour growth as described in US Patent No. US4347240.

It is unknown whether intact bacteria are required to exert an immunomodulatory effect or if individual active components of the invention can be utilized alone. Proinflammatory components of certain bacterial strains have been identified. The proinflammatory effects of gram-negative bacteria are mediated by lipopolysaccharide (LPS). LPS alone induces a proinflammatory network, partially due to LPS binding to the CD14 receptor on monocytes. It is assumed that components of probiotic bacteria possess immunomodulatory activity, due to the effects of the whole cell. Upon isolation of these components, pharmaceutical grade manipulation is anticipated.

Interleukin-8 (IL-8) is one of the cytokines comprising the Macrophage Inflammatory protein family (MIP). The MIP-1 and -2 families represent a group of proteins which are chemotactic factors for leukocytes and fibroblasts. This family of proteins are also called intercrines, as cells other than macrophages are capable of synthesizing them. These cells include T and B cells, fibroblasts, endothelial cells, keratinocytes, smooth muscle cells, synovial cells, neutrophils, chondrocytes, hepatocytes, platelets and tumour cells. MIP-1α -1β, connective tissue activating protein (CTAP), platelet factor 4 (PF4) and IL-8 stimulate neutrophil chemotaxis. Monocyte chemotactic protein (MCP-1) and RANTES are chemotactic for monocytes, IL-8 for neutrophils and lymphocytes while PF4 and CTAP are chemotactic for fibroblasts. Roles other than chemotaxis have been described for some of these family members. MCP-1 stimulates monocyte cytostatic activity and superoxide anion release. CTAP and PF4
increase fibroblast proliferation, IL-8 increases vascular permeability while MIP-1α and -1β are pyrogenic. IL-8 is intimately involved in inflammatory responses within the gastrointestinal tract. Stimulation of IL-8 (and other proinflammatory cytokines) could contribute to the development of gastrointestinal lesions therefore it is important that probiotic bacteria should not stimulate the production of this cytokine.

IL-10 is produced by T cells, B cells, monocytes and macrophages. This cytokine augments the proliferation and differentiation of B cells into antibody secreting cells. IL-10 exhibits mostly anti-inflammatory activities. It up-regulates IL-1RA expression by monocytes and suppresses the majority of monocyte inflammatory activities. IL-10 inhibits monocyte production of cytokines, reactive oxygen and nitrogen intermediates, MHC class II expression, parasite killing and IL-10 production via a feed back mechanism (7). This cytokine has also been shown to block monocyte production of intestinal collagenase and type IV collagenase by interfering with a PGE2-cAMP dependant pathway and therefore may be an important regulator of the connective tissue destruction seen in chronic inflammatory diseases.

IL-12 is a heterodimeric protein of 70 kD composed of two covalently linked chains of 35 kD and 40 kD. It is produced primarily by antigen presenting cells, such as macrophages, early in the inflammatory cascade. Intracellular bacteria stimulate the production of high levels of IL-12. It is a potent inducer of IFNγ production and activator of natural killer cells. IL-12 is one of the key cytokines necessary for the generation of cell mediated, or Th1, immune responses primarily through its ability to prime cells for high IFNγ production (8). IL-12 induces the production of IL-10 which feedback inhibits IL-12 production thus restricting uncontrolled cytokine production. TGF-β also down-regulates IL-12 production. IL-4 and IL-13 can have stimulatory or inhibitory effects on IL-12 production. Inhibition of IL-12 in vivo may have some therapeutic value in the treatment of Th1 associated inflammatory disorders, such as multiple sclerosis (9).
Interferon-gamma (IFNγ) is primarily a product of activated T lymphocytes and due to variable glycosylation it can be found ranging from 20 to 25 kDa in size. This cytokine synergizes with other cytokines resulting in a more potent stimulation of monocytes, macrophages, neutrophils and endothelial cells. IFNγ also amplifies lipopolysaccharide (LPS) induction of monocytes and macrophages by increasing cytokine production (10), increased reactive intermediate release, phagocytosis and cytotoxicity. IFNγ induces, or enhances the expression of major histocompatibility complex class II (MHC class II) antigens on monocytic cells and cells of epithelial, endothelial and connective tissue origin. This allows for greater presentation of antigen to the immune system from cells within inflamed tissues. IFNγ may also have anti-inflammatory effects. This cytokine inhibits phospholipase A₂, thereby decreasing monocyte production of PGE₂ and collagenase (11). IFNγ may also modulate monocyte and macrophage receptor expression for TGFβ, TNFα and C5a (11) thereby contributing to the anti-inflammatory nature of this cytokine. Probiotic stimulation of this cytokine would have variable effects in vivo depending on the current inflammatory state of the host, stimulation of other cytokines and the route of administration.

TNFα is a proinflammatory cytokine which mediates many of the local and systemic effects seen during an inflammatory response. This cytokine is primarily a monocyte or macrophage derived product but other cell types including lymphocytes, neutrophils, NK cells, mast cells, astrocytes, epithelial cells endothelial cells and smooth muscle cells can also synthesise TNFα. TNFα is synthesised as a prohormone and following processing the mature 17.5 kDa species can be observed. Purified TNFα has been observed as dimers, trimers and pentamers with the trimeric form postulated to be the active form in vivo. Three receptors have been identified for TNFα. A soluble receptor seems to function as a TNFα inhibitor (12) while two membrane bound forms have been identified with molecular sizes of 60 and 80 kDa respectively. Local TNFα production at inflammatory sites can be induced with endotoxin and the glucocorticoid dexamethasone inhibits cytokine production (13).
TNFα production results in the stimulation of many cell types. Significant anti-viral effects could be observed in TNFα treated cell lines (14) and the IFNs synergise with TNFα enhancing this effect. Endothelial cells are stimulated to produce procoagulant activity, expression of adhesion molecules, IL-1, hematopoietic growth factors, platelet activating factor (PAF) and arachidonic acid metabolites. TNFα stimulates neutrophil adherence, phagocytosis, degranulation (15), reactive oxygen intermediate production and may influence cellular migration. Leucocyte synthesis of GM-CSF, TGFβ, IL-1, IL-6, PGE\textsubscript{2} and TNFα itself can all be stimulated upon TNFα administration (16, 17). Programmed cell death (apoptosis) can be delayed in monocytes (18) while effects on fibroblasts include the promotion of chemotaxis and IL-6, PGE\textsubscript{2} and collagenase synthesis. While local TNFα production promotes wound healing and immune responses, the dis-regulated systemic release of TNFα can be severely toxic with effects such as cachexia, fever and acute phase protein production being observed (19).

The invention will be more clearly understood from the following examples.

**Example 1: Characterisation of bacteria isolated from resected and washed human gastrointestinal tract. Demonstration of probiotic traits.**

**Isolation of Probiotic Bacteria**

Appendices and sections of the large and small intestine of the human gastrointestinal tract (G.I.T.) obtained during reconstructive surgery, were screened for probiotic bacterial strains. All samples were stored immediately after surgery at -80°C in sterile containers.

Frozen tissues were thawed, weighed and placed in cysteinated (0.05%) one quarter strength Ringers’ solution. The sample was gently shaken to remove loosely adhering microorganisms (termed –wash ‘W’). Following transfer to a second volume of
Ringer’s solution, the sample was vortexed for 7 mins to remove tightly adhering bacteria (termed ‘sample S’). In order to isolate tissue embedded bacteria, samples 356, 176 and A were also homogenized in a Braun blender (termed ‘homogenate H’). The solutions were serially diluted and spread-plated (100μl) on the following agar media: RCM (reinforced clostridia media) and RCM adjusted to pH 5.5 using acetic acid; TPY (trypticase, peptone and yeast extract); MRS (deMann, Rogosa and Sharpe); ROG (acetate medium (SL) of Rogosa); LLA (liver-lactose agar of Lapiere); BHI (brain heart infusion agar); LBS (Lactobacillus selective agar) and TSAYE (tryptone soya agar supplemented with 0.6% yeast extract). TPY and MRS agar supplemented with propionic acid (TPYP) was also used. All agar media was supplied by Oxoid Chemicals with the exception of TPY agar. Plates were incubated in anaerobic jars (BBL, Oxoid) using CO₂ generating kits (Anaerocult A, Merck) for 2-5 days at 37°C.

Gram positive, catalase negative rod-shaped or bifurcated/pleomorphic bacteria isolates were streaked for purity on to complex non-selective media (MRS and TPY). Isolates were routinely cultivated in MRS or TPY medium unless otherwise stated at 37°C under anaerobic conditions. Presumptive Lactobacillus were stocked in 40% glycerol and stored at -20°C and -80°C.

Seven tissue sections taken from the G.I.T. were screened for the presence of strains belonging to the Lactobacillus genera. There was some variation between tissue samples as shown in Table 1 below. Samples A (ileum) and 316 (appendix) had the lowest counts with approximately 10³ cells isolated per gram of tissue. In comparison, greater 10³ cfu/g tissue were recovered from the other samples. Similar numbers of bacteria were isolated during the ‘wash’ and ‘sample’ steps with slightly higher counts in the ‘sample’ solutions of 433 (ileal-caecal). Table 1 shows the bacterial counts of tissue samples expressed as colony forming units per gram (cfu/ml) of tissue.

<table>
<thead>
<tr>
<th>Isolation Medium</th>
<th>Tissue Sample No.</th>
<th>A</th>
<th>176</th>
<th>356</th>
<th>312</th>
<th>316</th>
<th>423</th>
<th>433</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Fermentation and growth characteristics**

Metabolism of the carbohydrate glucose and the subsequent organic acid end-products were examined using an LKB Bromma, Aminex HPX-87H High Performance Liquid Chromatography column. The column was maintained at 60°C with a flow rate of 0.6 ml/min (constant pressure). The HPLC buffer used was 0.01 N H₂SO₄. Prior to analysis, the column was calibrated using 10 mM citrate, 10mM glucose, 20 mM lactate and 10 mM acetate as standards. Cultures were propagated in modified MRS broth (*Lactobacillus* strains) for 1-2 days at 37°C anaerobically. Following centrifugation for 10 min at 14,000 g, the supernatant was diluted 1:5 with HPLC buffer and 200 µl was analysed in the HPLC. All supernatants were analysed in duplicate.
Biochemical and physiological traits of the bacterial isolates were determined to aid identification. Nitrate reduction, indole formation and expression of β-galactosidase activity were assayed. Growth at both 15°C and 45°C, growth in the presence of increasing concentrations of NaCl up to 5.0% and protease activity on gelatin were determined. Growth characteristics of the strains in litmus milk were also assessed.

Approximately fifteen hundred catalase negative bacterial isolates from different samples were chosen and characterised in terms of their Gram reaction, cell size and morphology, growth at 15°C and 45°C and fermentation end-products from glucose (data not shown). Greater than sixty percent of the isolates tested were Gram positive, homofermentative cocci (HOMO-) arranged either in tetrads, chains or bunches. Eighteen percent of the isolates were Gram negative rods and heterofermentative coccobacilli (HETERO-). The remaining isolates (twenty two percent) were predominantly homofermentative coccobacilli. Thirty eight strains were characterised in more detail- 13 isolates from 433; 4 from 423; 8 from 312; 9 from 356; 3 from 176 and 1 from 316. All thirty eight isolates tested negative both for nitrate reduction and production of indole from tryptophan. Growth at different temperatures, concentrations of NaCl and gelatin hydrolysis are recorded in Table 2 below.
Table 2

<table>
<thead>
<tr>
<th>Strain</th>
<th>Source</th>
<th>Fermentation Pattern</th>
<th>Temp. Profiles</th>
<th>% NaCl*</th>
<th>Gelatin Hydrolysis</th>
<th>Reactions in litmus milk pH**</th>
<th>REDn</th>
</tr>
</thead>
<tbody>
<tr>
<td>AH101</td>
<td>S1 MRS</td>
<td>HOMO-</td>
<td>+ -</td>
<td>5.0</td>
<td>-</td>
<td>5.5</td>
<td>RpCp</td>
</tr>
<tr>
<td>AH104</td>
<td>S0 MRS</td>
<td>HOMO-</td>
<td>+ +(s)</td>
<td>5.0</td>
<td>-</td>
<td>5.5</td>
<td>RpCp</td>
</tr>
<tr>
<td>AH111</td>
<td>S1 LBS</td>
<td>HOMO-</td>
<td>+ +(s)</td>
<td>5.0</td>
<td>-</td>
<td>5.9</td>
<td>Rp</td>
</tr>
<tr>
<td>AH112</td>
<td>S0 LBS</td>
<td>HOMO-</td>
<td>+(s) +(s)</td>
<td>0.8</td>
<td>-</td>
<td>5.3</td>
<td>RpCp</td>
</tr>
<tr>
<td>AH113</td>
<td>S0 MRS</td>
<td>HOMO-</td>
<td>+ +</td>
<td>5.0</td>
<td>-</td>
<td>5.6</td>
<td>RpCp</td>
</tr>
</tbody>
</table>

-, Negative for reaction/growth; +, Positive reaction/growth; +(s), slow growth; REDn, Reduction; Rp, Partial reduction, Cp, Partial clotting;

*Maximum concentration of NaCl in which the strain will grow

**pH after 24 h incubation in litmus milk at 37°C.

Species identification

The API 50CHL (BioMerieux SA, France) system was used to tentatively identify the Lactobacillus species by their carbohydrate fermentation profiles. Overnight MRS cultures were harvested by centrifugation and resuspended in the suspension medium provided with the kit. API strips were inoculated and analysed (after 24 and 48 h) according to the manufacturers’ instructions. Identity of the Lactobacillus sp. was then checked by SDS-Polyacrylamide gel electrophoresis analysis (SDS-PAGE) of total cell protein (Bruno Pot, University of Ghent, Belgium, personal communication). Finally, 16s RNA analysis and ribotyping were used to confirm strain identity.

The API 50CHL allowed rapid identification of the Lactobacillus isolates. Analysis of total cell protein of the Lactobacillus sp. (Bruno Pot, personal communication) by SDS-PAGE, 16s RNA analysis and ribotyping revealed further information on the specific species. Table 3 below shows the identification of the 5 Lactobacillus strains by four different techniques.
Table 3

<table>
<thead>
<tr>
<th>Strain</th>
<th>Sugar fermentation profiles</th>
<th>Total cell protein (SDS-PAGE)*</th>
<th>16s RNA analysis</th>
<th>Ribotyping</th>
</tr>
</thead>
<tbody>
<tr>
<td>AH101</td>
<td><em>L. pentosus</em> subsp. salivarius</td>
<td><em>L. salivarius</em> L. casei subsp. paracasei</td>
<td>L. paracasei subsp. paracasei</td>
<td></td>
</tr>
<tr>
<td>AH104</td>
<td><em>L. pentosus</em> subsp. paracasei</td>
<td>L. paracasei L. casei subsp. paracasei</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH111</td>
<td><em>L. paracasei</em> subsp. paracasei</td>
<td>L. paracasei L. casei subsp. paracasei</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH112</td>
<td><em>L. paracasei</em> subsp. paracasei</td>
<td>L. paracasei L. casei L. plantarum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH113</td>
<td><em>L. paracasei</em> subsp. paracasei</td>
<td>L. paracasei L. casei subsp. paracasei</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Enzyme Activity Profiles**

The API ZYM system (BioMerieux, France) was used for semi-quantitative measurement of constitutive enzymes produced by *Lactobacillus* isolates. Bacterial cells from the late logarithmic growth phase were harvested by centrifugation at 14,000g for 10 mins. The pelleted cells were washed and resuspended in 50mM phosphate buffer, pH 6.8 to the same optical density. The strips were inoculated in accordance with the manufacturer’s instructions, incubated for 4 h at 37°C and colour development recorded.

The enzyme activity profiles of the 5 strains AH101, AH104, AH111, AH112 and AH113 are presented in Table 4 below. None of the strains exhibited lipase, trypsin, α-glucuronidase or α-mannosidase activities.
Table 4

<table>
<thead>
<tr>
<th></th>
<th>AH101</th>
<th>AH104</th>
<th>AH111</th>
<th>AH112</th>
<th>AH113</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkaline Phosphate</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Esterase</td>
<td>4</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Esterase Lipase</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Lipase</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Leucine Arylamidase</td>
<td>5</td>
<td>2</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Valine Arylamidase</td>
<td>2</td>
<td>0</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Cystine Arylamidase</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Trypsin</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>α-Chymotrypsin</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Phosphate acid</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Phosphohydrolase</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>α-Galactosidase</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>β-Galactosidase</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>β-glucuronidase</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>α-Glucosidase</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>β-Glucosidase</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>α-Glucosaminidase</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>α-Mannosidase</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>α-Fucosidase</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Antibiotic sensitivity profiles

Antibiotic sensitivity profiles of the isolates were determined using the 'disc susceptibility' assay. Cultures were grown up in the appropriate broth medium for 24-48h spread-plated (100μl) onto agar media and discs containing known concentrations of the antibiotics were placed onto the agar. Strains were examined for antibiotic sensitivity after 1-2 days incubation at 37°C under anaerobic conditions. Strains were considered sensitive if zones of inhibition of 1mm or greater were seen.
Antibiotics of human clinical importance were used to ascertain the antibiotic sensitivity (µg/ml) profiles of each of the 5 *Lactobacillus casei* strains as shown in Table 5 below. Each of the lactobacilli tested was sensitive to ampicillin, amoxicillin and rifampicin, with 4 of the 5 strains sensitive to ceftriaxone, ciprofloxacin, cephradine and chloramphenicol.

<table>
<thead>
<tr>
<th></th>
<th>AH101</th>
<th>AH104</th>
<th>AH111</th>
<th>AH112</th>
<th>AH113</th>
</tr>
</thead>
<tbody>
<tr>
<td>NET 10</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
</tr>
<tr>
<td>AMP 25</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>AMC 30</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>AK 30</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
</tr>
<tr>
<td>W 1.25</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>TEC 30</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>R</td>
</tr>
<tr>
<td>CXM 30</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>CTX 30</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>ZOX 30</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>ND</td>
<td>R</td>
</tr>
<tr>
<td>CRO 30</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>CIP 5</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>CN 10</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>R</td>
</tr>
<tr>
<td>MTZ 5</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>CE 30</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>R</td>
</tr>
<tr>
<td>RD 5</td>
<td>S</td>
<td>S</td>
<td>ND</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>V 5</td>
<td>S</td>
<td>ND</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>C 10</td>
<td>R</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>TE 10</td>
<td>S</td>
<td>ND</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>E 5</td>
<td>R</td>
<td>ND</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>NA 30</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
</tbody>
</table>

R, resistant; S, sensitive; ND, not determined
Growth of lactobacilli at low pH

Human gastric juice was obtained from healthy subjects by aspiration through a nasogastric tube (Mercy Hospital, Cork, Ireland). It was immediately centrifuged at 13,000 g for 30 min to remove all solid particles, sterilised through 0.45 μm and 0.2 μm filters and divided into 40 ml aliquots which were stored at 4°C and −20°C.

The pH and pepsin activity of the samples were measured prior to experimental use. Pepsin activity was measured using the quantitative haemoglobin assay. Briefly, aliquots of gastric juice (1ml) were added to 5 ml of substrate (0.7 M urea, 0.4% (w/v) bovine haemoglobin (Sigma Chemical Co., 0.25 M KCl-HCl buffer, pH 2.0) and incubated at 25°C. Samples were removed at 0, 2, 4, 6, 8, 10, 20 and 30 min intervals. Reactions were terminated by the addition of 5% trichloroacetic acid (TCA) and allowed to stand for 30 min without agitation. Assay mixtures were then filtered (Whatman, no. 113), centrifuged at 14,000 g for 15 min and absorbance at 280 nm was measured. One unit of pepsin enzyme activity was defined as the amount of enzyme required to cause an increase of 0.001 units of A280 nm per minute at pH 2.0 measured as TCA-soluble products using haemoglobin as substrate.

To determine whether growth of the Lactobacillus strains occurred at low pH values equivalent to those found in the stomach, overnight cultures were inoculated (1%) into fresh MRS broth adjusted to pH 4.0, 3.0, 2.0 and 1.0 using 1N HCl. At regular intervals aliquots (1.5ml) were removed, optical density at 600nm (OD600) was measured and colony forming units per ml (cfu/ml) calculated using the plate count method. Growth was monitored over a 24-48h period.

Survival of the strains at low pH in vitro was investigated using two assays:

(a) Cells were harvested from fresh overnight cultures, washed twice in phosphate buffer (pH 6.5) and resuspended in MRS broth adjusted to pH 3.5, 3.0, 2.5, and 2.0 (with 1N HCl) to a final concentration of approximately 10^8 cfu/ml for the lactobacilli. Cells were incubated at 37°C and survival measured at intervals of 5, 30, 60 and 120 min using the plate count method.
(b) The *Lactobacillus* strains were propagated in buffered MRS broth (pH 6.0) daily for a 5 day period. The cells were harvested, washed and resuspended in pH adjusted MRS broth and survival measured over a 2 h period using the plate count method.

To determine the ability of the lactobacilli to survive passage through the stomach, an ex-*vivo* study was performed using human gastric juice. Cells from fresh overnight cultures were harvested, washed twice in buffer (pH 6.5) and resuspended in human gastric juice to a final concentration of $10^6$-$10^8$ cfu/ml, depending on the strain. Survival was monitored over a 30-60 min incubation period at 37°C. The experiment was performed using gastric juice at pH ~ 1.2 (unadjusted) and pH 2.0 and 2.5 (adjusted using 1N NaOH).

Each of the *Lactobacillus* strains grew normally at pH 6.8 and pH 4.5 reaching stationary phase after 8 h with a doubling time of 80-100 min. At pH 3.5 growth was restricted with doubling times increasing to 6-8h. No growth was observed at pH 2.5 or lower, therefore, survival of the strains at low pH was examined.

Each of the *Lactobacillus* strains, AH101, AH104, AH111, AH112 and AH113 was resistant to pH values 3.5, 3.0, 2.5 and 2.0 (data not shown).

To determine the ability of the *Lactobacillus* strains to survive conditions encountered in the human stomach, viability of each of the 5 strains was tested in human gastric juice at pH 1.2 and pH 2.5 in Table 6 below. Survival is expressed at $\log_{10}$ cfu/ml (nd, not determined).
Table 6

<table>
<thead>
<tr>
<th>STRAIN</th>
<th>pH</th>
<th>0</th>
<th>5</th>
<th>30</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactobacillus sp.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH101</td>
<td>1.2</td>
<td>9.16</td>
<td>9.00</td>
<td>4.85</td>
<td>nd</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>9.32</td>
<td>9.31</td>
<td>8.12</td>
<td>6.63</td>
</tr>
<tr>
<td>AH104</td>
<td>1.2</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>7.24</td>
<td>7.26</td>
<td>4.27</td>
<td>4.71</td>
</tr>
<tr>
<td>AH111</td>
<td>1.2</td>
<td>9.07</td>
<td>6.69</td>
<td>2.82</td>
<td>nd</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>9.22</td>
<td>9.13</td>
<td>9.18</td>
<td>8.98</td>
</tr>
<tr>
<td>AH112</td>
<td>1.2</td>
<td>8.92</td>
<td>5.69</td>
<td>2.92</td>
<td>nd</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>8.69</td>
<td>8.72</td>
<td>5.55</td>
<td>4.79</td>
</tr>
<tr>
<td>AH113</td>
<td>1.2</td>
<td>9.25</td>
<td>9.00</td>
<td>2.88</td>
<td>nd</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>9.59</td>
<td>9.59</td>
<td>5.48</td>
<td>4.48</td>
</tr>
</tbody>
</table>

ND, not determined

Growth of cultures in the presence of bile

Fresh cultures were streaked onto MRS agar plates supplemented with bovine bile (B-8381, Sigma Chemical Co. Ltd., Poole) at concentrations of 0.3, 1.0, 1.5, 5.0 and 7.5% (w/v) and porcine bile (B-8631, Sigma Chemical Co. Ltd., Poole) at concentrations of 0.3, 0.5, 1.0, 1.5, 5.0 and 7.5% (w/v). Plates were incubated at 37°C under anaerobic conditions and growth was recorded after 24-48h.

Bile samples, isolated from several human gall-bladders, were stored at -80°C before use. For experimental work, bile samples were thawed, pooled and sterilised at 80°C for 10 min. Bile acid composition of human bile was determined using reverse-phase High Performance Liquid Chromatography (HPLC) in combination with a pulsed amperometric detector according to the method of Dekker et al. (20). Human bile was added to MRS/TPY agar medium at a concentration of 0.3% (v/v). Freshly streaked cultures were examined for growth after 24 and 48 h.
Human gall-bladder bile possesses a bile acid concentration of 50-100 mM and dilution in the small intestine lowers this concentration to 5-10 mM. Furthermore, under physiological conditions, bile acids are found as sodium salts. Therefore, cultures were screened for growth on MRS agar plates containing the sodium salt of each of the following bile acids (Sigma Chemical Co. Ltd., Poole):

(a) *conjugated* form: taurocholic acid (TCA); glycocholic acid (GCA); taurodeoxycholic acid (TDCA); glycodyoxycholic acid (GDCA); taurochenodeoxycholic acid (TCDCa) and glycochenodeoxycholic acid (GCDCA); (b) *deconjugated* form: lithocholic acid (LCA); chenodeoxycholic acid (CDCA); deoxycholic acid (DCA) and cholic acid (CA). For each bile acid concentrations of 1, 3 and 5 mM were used. Growth was recorded after 24 and 48 h anaerobic incubation.

Both a qualitative (agar plate) and a quantitative (HPLC) assay were used to determine deconjugation activity of each of the strains.

*Plate assay:* All the cultures were streaked on MRS agar plates supplemented with (a) 0.3% (w/v) porcine bile, (b) 3 mM TDCA or (c) 3 mM GDCA. Deconjugation was observed as an opaque precipitate surrounding the colonies.

*High Performance Liquid Chromatography (HPLC):* Analysis of in vitro deconjugation of human bile was performed using HPLC. Briefly, overnight cultures were inoculated (5%) into MRS broth supplemented with 0.3% (v/v) human bile and were incubated anaerobically at 37°C. At various time intervals over a 24 h period, samples (1 ml) were removed and centrifuged at 14,000 rpm for 10 min. Undiluted cell-free supernatant (30 μl) was then analysed by HPLC.

*Lactobacillus casei* AH101, AH104, AH111, AH112 and AH113 were capable of growth (bile acid resistance) on three sources of bile used. It was observed that resistance to bovine bile was much higher than to porcine bile. The *Lactobacillus*
strains were resistant to concentrations up to and including 5.0% bovine bile (data not shown).

Porcine bile was more inhibitory as shown in Table 7 below.

Table 7

<table>
<thead>
<tr>
<th>STRAIN</th>
<th>0.0</th>
<th>0.3</th>
<th>0.5</th>
<th>1.0</th>
<th>1.5</th>
<th>5.0</th>
<th>7.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactobacillus sp.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH101</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>AH104</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AH111</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AH112</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AH113</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Regardless of the bile resistance profiles in the presence of both bovine and porcine bile, each of the Lactobacillus strains grew to confluence at the physiological concentration of 0.3% (v/v) human bile (data not shown).

Each of the Lactobacillus casei strains, when analysed specifically for its resistance to individual bile acids, grew well in the presence of taurine conjugated bile acids. Isolates from each of the strains grew to confluence on agar medium containing up to and including 5 mM of taurine conjugates TCA, TDCA and TCDCA. Of the glycine conjugates tested, in general, GCDCA was the most inhibitory. GDCA was less inhibitory and GCA was the least inhibitory of the three glycine conjugates as shown in Table 8 below. Interestingly, none of the glycine conjugates were inhibitory to the growth of AH101. Each strain grew on agar medium supplemented with 5 mM GCA.
Table 8

<table>
<thead>
<tr>
<th>STRAIN</th>
<th>GCDCA</th>
<th>GDCA</th>
<th>GCA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 1 3 5</td>
<td>0 1 3 5</td>
<td>0 1 3 5</td>
</tr>
<tr>
<td><em>Lactobacillus</em> sp.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AH101</td>
<td>+ + + +</td>
<td>+ + + +</td>
<td>+ + + +</td>
</tr>
<tr>
<td>AH104</td>
<td>+ + - -</td>
<td>+ + + -</td>
<td>+ + + +</td>
</tr>
<tr>
<td>AH111</td>
<td>+ + - -</td>
<td>+ + - -</td>
<td>+ + + +</td>
</tr>
<tr>
<td>AH112</td>
<td>+ + - -</td>
<td>+ + + -</td>
<td>+ + + +</td>
</tr>
<tr>
<td>AH113</td>
<td>+ + - -</td>
<td>+ + + -</td>
<td>+ + + +</td>
</tr>
</tbody>
</table>

-; no growth; +; confluent growth

Growth in the presence of deconjugated bile acids was also tested. Each strain was resistant to concentrations of 5 mM LCA. Growth in the presence of CA was tested. As shown in Table 9 below, 4 of the 5 strains grew in the presence of 5mM CA. No growth was observed in the presence of 1 mM CDCA. (data not shown)

Table 9

<table>
<thead>
<tr>
<th>STRAIN</th>
<th>CHOLIC ACID (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 1 3 5</td>
</tr>
<tr>
<td><em>Lactobacillus</em> sp.</td>
<td></td>
</tr>
<tr>
<td>AH101</td>
<td>+ + + +</td>
</tr>
<tr>
<td>AH104</td>
<td>+ + + +</td>
</tr>
<tr>
<td>AH111</td>
<td>+ + - -</td>
</tr>
<tr>
<td>AH112</td>
<td>+ + + +</td>
</tr>
<tr>
<td>AH113</td>
<td>+ + + +</td>
</tr>
</tbody>
</table>
Detection of antimicrobial activity

Antimicrobial activity was detected using the deferred method (21). Indicators used in the initial screening were L. innocua, L. fermentum KLD, P. fluorescens and E. coli V157. Briefly, the lactobacilli (MRS) were incubated for 12-16 h and 36-48 h, respectively. Ten-fold serial dilutions were spread-plated (100μl) onto MRS/TPY agar medium. After overnight incubation, plates with distinct colonies were overlayed with the indicator bacterium. The indicator lawn was prepared by inoculating a molten overlay with 2% (v/v) of an overnight indicator culture which was poured over the surface of the inoculated MRS plates. The plates were re-incubated overnight under conditions suitable for growth of the indicator bacterium. Indicator cultures with inhibition zones greater than 1 mm in radius were considered sensitive to the test bacterium.

Inhibition due to bacteriophage activity was excluded by flipping the inoculated MRS/TPY agar plates upside down and overlaying with the indicator. Bacteriophage cannot diffuse through agar.

*Lactobacillus casei* AH101, AH104, AH111, AH112 and AH113 were screened for inhibitory activity using *Ls. innocua, L. fermentum* KLD, *P. fluorescens* and *E. coli* as indicator microorganisms. When the test strains were inoculated on unbuffered MRS, inhibition of the four indicators was observed. Zones ranging in size from 1 mm to 5 mm were measured. Inhibition of *Ls. innocua* by each of the lactobacilli produced the largest zones.

**Example 2: Adhesion of probiotic bacteria to gastrointestinal epithelial cells.**

The adhesion of the probiotic strains was carried out using a modified version of a previously described method (22). The monolayers of HT-29 and Caco-2 cells were prepared on sterile 22mm² glass coverslips, which were placed in Corning tissue culture dishes, at a concentration of 4 X 10⁴ cells/ml. Cells were fed fresh medium every 2 days. After ~10 days, and differentiation of the monolayer had occurred, the
monolayers were washed twice with Phosphate Buffered Saline (PBS). Antibiotic-free DMEM (2ml) and 2ml of ~18h *Lb.* suspension containing ~10⁹ cfu/ml were added to each dish and cells were incubated for 2h at 37⁰C in a humidified atmosphere containing 5% CO₂. After incubation, the monolayers were washed 5 times with PBS, fixed in methanol (BDH Laboratory Supplies, Poole, UK) for 3 min, Gram stained (Gram Stain Set, Merck) and examined microscopically under oil immersion. For each glass coverslip monolayer the number of adherent bacteria per 20 epithelial cells was counted in 10 microscopic fields. The mean and standard error of adherent bacteria per 20 epithelial cells was calculated. Each adhesion assay was carried out in duplicate.

In a second method, after washing 5 times in PBS, adhering bacteria were removed by vortexing the monolayers rigorously in cold sterile H₂O. Bacterial cells were enumerated by serial dilution in quarter strength Ringer's solution (Oxoid) and incubation on MRS (lactobacilli).

Each of the 5 *Lactobacillus* strains, AH101, AH104, AH111, AH112 and AH113 adhered to gastrointestinal epithelial cells (Fig. 1). These probiotic strains would be suitable as vaccine/drug delivery vehicles as they adhere to the gastrointestinal epithelium and therefore interacts with the relevant host tissue.

**Example 3: Determination of the effect of *Lactobacillus casei* strains on PBMC cytokine production.**

Peripheral blood mononuclear cells were isolated from healthy donors (n=19) by density gradient centrifugation. PBMCs were stimulated with the probiotic bacterial strains for a 72 hour period at 37⁰C. At this time culture supernatants were collected, centrifuged, aliquoted and stored at -70⁰C until being assessed for IL-8 and IFNγ levels using ELISAs (Boehringer Mannheim).
AH101, AH104, AH112 and AH113 stimulated the production of IFN\(\gamma\) by cultured PBMCs (Fig. 2).

AH113 stimulated IL-10 production by PBMCs while AH101, AH104, AH111 & AH112 did not alter levels of this cytokine (Fig. 3).

AH101, AH104, AH111, AH112 & AH113 induced IL-12 secretion by PBMCs (Fig. 4).

Neither AH111 nor AH112 stimulated IL-8 production \textit{in vitro}, from PBMCs isolated from healthy donors. Indeed, IL-8 levels were significantly reduced following co-incubation with AH111 (Fig. 5).

\textbf{Example 4: Determination of cytokine levels in an epithelial/PBMC co-culture model following incubation with AH112.}

The appropriate \textit{in vitro} model with physiological relevance to the intestinal tract is a culture system incorporating epithelial cells, T cells, B cells, monocytes and the bacterial strains. To this end, human Caco-2 epithelial cells were seeded at 5x10^5 cells/ml on the apical surface of 25 mm transwell inserts with a pore size of 3\(\mu\)m (Costar). These cells were cultured for four weeks in RPMI 1640, supplemented with 10% foetal calf serum, glutamine, penicillin and streptomycin, at 37\(^\circ\)C in a 5% \(\text{CO}_2\) environment. Culture media was changed every 3 days. When the epithelial cells were fully differentiated, human peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation. 1x10^6 washed PBMCs was incubated basolaterally to the epithelial cells and cultured with 1x10^7 probiotic bacteria. Controls contained media alone. No direct cell-cell contact between PBMCs and epithelial cells was possible in this model system and cellular communication was mediated solely by soluble factors.

Following 72 hours of incubation with the relevant bacterial strains, cell culture supernatants were removed, aliquoted and stored at \(-70^\circ\text{C}\). TNF\(\alpha\) extracellular
cytokine levels were measured using standard ELISA kits (R&D Systems). TNFα levels and were measured, in duplicate, using PBMCs from 3 healthy volunteers.

Following incubation of epithelial cell-PBMC co-cultures with probiotic bacteria, TNFα cytokine levels were examined by ELISAs (Fig. 6). Co-incubation with AH112 did not stimulate TNFα production in this model.

**Immunomodulation**

The human immune system plays a significant role in the aetiology and pathology of a vast range of human diseases. Hyper and hypo-immune responsiveness results in, or is a component of, the majority of disease states. One family of biological entities, termed cytokines, are particularly important to the control of immune processes. Perturbances of these delicate cytokine networks are being increasingly associated with many diseases. These diseases include but are not limited to inflammatory disorders, immunodeficiency, inflammatory bowel disease, irritable bowel syndrome, cancer (particularly those of the gastrointestinal and immune systems), diarrhoeal disease, antibiotic associated diarrhoea, paediatric diarrhoea, appendicitis, autoimmune disorders, multiple sclerosis, Alzheimer’s disease, rheumatoid arthritis, coeliac disease, diabetes mellitus, organ transplantation, bacterial infections, viral infections, fungal infections, periodontal disease, urogenital disease, sexually transmitted disease, HIV infection, HIV replication, HIV associated diarrhoea, surgical associated trauma, surgical-induced metastatic disease, sepsis, weight loss, anorexia, fever control, cachexia, wound healing, ulcers, gut barrier function, allergy, asthma, respiratory disorders, circulatory disorders, coronary heart disease, anaemia, disorders of the blood coagulation system, renal disease, disorders of the central nervous system, hepatic disease, ischaemia, nutritional disorders, osteoporosis, endocrine disorders, epidermal disorders, psoriasis and acne vulgaris. The effects on cytokine production are specific for each of the probiotic strains examined. Thus specific probiotic strains may be selected for normalising an exclusive cytokine imbalance particular for a
specific disease type. Customisation of disease specific therapies can be accomplished using a selection of the probiotic strains listed above.

**Immune Education**

The enteric flora is important to the development and proper function of the intestinal immune system. In the absence of an enteric flora, the intestinal immune system is underdeveloped, as demonstrated in germ free animal models, and certain functional parameters are diminished, such as macrophage phagocytic ability and immunoglobulin production (23). The importance of the gut flora in stimulating non-damaging immune responses is becoming more evident. The increase in incidence and severity of allergies in the western world has been linked with an increase in hygiene and sanitation, concomitant with a decrease in the number and range of infectious challenges encountered by the host. This lack of immune stimulation may allow the host to react to non-pathogenic, but antigenic, agents resulting in allergy or autoimmunity. Deliberate consumption of a series of non-pathogenic immunomodulatory bacteria would provide the host with the necessary and appropriate educational stimuli for proper development and control of immune function.

**Inflammation**

Inflammation is the term used to describe the local accumulation of fluid, plasma proteins and white blood cells at a site that has sustained physical damage, infection or where there is an ongoing immune response. Control of the inflammatory response is exerted on a number of levels (24). The controlling factors include cytokines, hormones (e.g. hydrocortisone), prostaglandins, reactive intermediates and leukotrienes. Cytokines are low molecular weight biologically active proteins that are involved in the generation and control of immunological and inflammatory responses, while also regulating development, tissue repair and haematopoiesis. They provide a means of communication between leukocytes themselves and also with other cell
types. Most cytokines are pleiotrophic and express multiple biologically overlapping activities. Cytokine cascades and networks control the inflammatory response rather than the action of a particular cytokine on a particular cell type (25). Waning of the inflammatory response results in lower concentrations of the appropriate activating signals and other inflammatory mediators leading to the cessation of the inflammatory response. TNFα is a pivotal proinflammatory cytokine as it initiates a cascade of cytokines and biological effects resulting in the inflammatory state. Therefore, agents which inhibit TNFα are currently being used for the treatment of inflammatory diseases, e.g. infliximab.

Pro-inflammatory cytokines are thought to play a major role in the pathogenesis of many inflammatory diseases, including inflammatory bowel disease (IBD). Current therapies for treating IBD are aimed at reducing the levels of these pro-inflammatory cytokines, including IL-8 and TNFα. Such therapies may also play a significant role in the treatment of systemic inflammatory diseases such as rheumatoid arthritis.

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, affecting up to 15-20% of the population at some stage during their life. The most frequent symptoms include abdominal pain, bowel habit disturbance, manifested by diarrhoea or constipation, flatulence, and abdominal distension. There are no simple tests to confirm diagnosis, and if no other organic disorders can be found for these symptoms, the diagnosis is usually IBS. Patients suffering from IBS represent as many as 25-50% of patients seen by gastroenterologists.

Many factors are thought to be involved in onset of symptoms including e.g. bout of gastroenteritis, abdominal or pelvic surgery, disturbances in the intestinal bacterial flora, perhaps due to antibiotic intake, and emotional stress. Compared with the general population, IBS sufferers may have a significantly reduced quality of life, are more likely to be absent from work, and use more healthcare resources. There are no effective medical treatments and to date, recommended therapies have included
antispasmodic agents, anti-diarrhoeal agents, dietary fibre supplements, drugs that modify the threshold of colonic visceral perception, analgesics and anti-depressants.

While each of the strains of the invention has unique properties with regard to cytokine modulation and microbial antagonism profiles, it should be expected that specific strains can be chosen for use in specific disease states based on these properties. For example, stimulation of IL-10 by AH113 suggests that this strain would be suitable for treatment of inflammatory states such as IBD or IBS. It also should be anticipated that combinations of strains from this panel with appropriate cytokine modulating properties and anti-microbial properties will enhance therapeutic efficacy.

The strains of the present invention may have potential application in the treatment of a range of inflammatory diseases, particularly if used in combination with other anti-inflammatory therapies, such as non-steroid anti-inflammatory drugs (NSAIDs) or Infliximab.

Cytokines and Cancer

The production of multifunctional cytokines across a wide spectrum of tumour types suggests that significant inflammatory responses are ongoing in patients with cancer. It is currently unclear what protective effect this response has against the growth and development of tumour cells in vivo. However, these inflammatory responses could adversely affect the tumour-bearing host. Complex cytokine interactions are involved in the regulation of cytokine production and cell proliferation within tumour and normal tissues (26, 27). It has long been recognized that weight loss (cachexia) is the single most common cause of death in patients with cancer and initial malnutrition indicates a poor prognosis. For a tumour to grow and spread it must induce the formation of new blood vessels and degrade the extracellular matrix. The inflammatory response may have significant roles to play in the above mechanisms, thus contributing to the decline of the host and progression of the tumour. Due to the
anti-inflammatory properties of *Lactobacillus paracasei* these bacterial strains may reduce the rate of malignant cell transformation. Furthermore, intestinal bacteria can produce, from dietary compounds, substances with genotoxic, carcinogenic and tumour-promoting activity and gut bacteria can activate pro-carcinogens to DNA reactive agents (28). In general, species of *Lactobacillus* have low activities of xenobiotic metabolizing enzymes compared to other populations within the gut such as bacteroides, eubacteria and clostridia. Therefore, increasing the number of *Lactobacillus* bacteria in the gut could beneficially modify the levels of these enzymes.

**Vaccine/Drug Delivery**

The majority of pathogenic organisms gain entry via mucosal surfaces. Efficient vaccination of these sites protects against invasion by a particular infectious agent. Oral vaccination strategies have concentrated, to date, on the use of attenuated live pathogenic organisms or purified encapsulated antigens (29). Probiotic bacteria, engineered to produce antigens from an infectious agent, *in vivo*, may provide an attractive alternative as these bacteria are considered to be safe for human consumption (GRAS status).

Murine studies have demonstrated that consumption of probiotic bacteria expressing foreign antigens can elicit protective immune responses. The gene encoding tetanus toxin fragment C (TTFC) was expressed in *Lactococcus lactis* and mice were immunized via the oral route. This system was able to induce antibody titers significantly high enough to protect the mice from lethal toxin challenge. In addition to antigen presentation, live bacterial vectors can produce bioactive compounds, such as immunostimulatory cytokines, *in vivo*. *L. lactis* secreting bioactive human IL-2 or IL-6 and TTFC induced 10-15 fold higher serum IgG titres in mice immunized intranasally (30). However, with this particular bacterial strain, the total IgA level was not increased by coexpression with these cytokines. Other bacterial strains, such as *Streptococcus gordonii*, are also being examined for their usefulness as mucosal
vaccines. Recombinant *S. gordonii* colonizing the murine oral and vaginal cavities induced both mucosal and systemic antibody responses to antigens expressed by this bacterial (31). Thus oral immunization using probiotic bacteria as vectors would not only protect the host from infection, but may replace the immunological stimuli that the pathogen would normally elicit thus contributing to the immunological education of the host.

**Prebiotics**

The introduction of probiotic organisms is accomplished by the ingestion of the microorganism in a suitable carrier. It would be advantageous to provide a medium that would promote the growth of these probiotic strains in the large bowel. The addition of one or more oligosaccharides, polysaccharides, or other prebiotics enhances the growth of lactic acid bacteria in the gastrointestinal tract. Prebiotics refers to any non-viable food component that is specifically fermented in the colon by indigenous bacteria thought to be of positive value, e.g. bifidobacteria, lactobacilli. Types of prebiotics may include those that contain fructose, xylose, soya, galactose, glucose and mannose. The combined administration of a probiotic strain with one or more prebiotic compounds may enhance the growth of the administered probiotic *in vivo* resulting in a more pronounced health benefit, and is termed synbiotic.

**Other active ingredients**

It will be appreciated that the probiotic strains may be administered prophylactically or as a method of treatment either on its own or with other probiotic and/or prebiotic materials as described above. In addition, the bacteria may be used as part of a prophylactic or treatment regime using other active materials such as those used for treating inflammation or other disorders especially those with an immunological involvement. Such combinations may be administered in a single formulation or as separate formulations administered at the same or different times and using the same or different routes of administration.
The invention is not limited to the embodiments herein before described which may be varied in detail.
References


Claims

1. A *Lactobacillus casei* strain or a mutant or variant thereof isolated from resected and washed human gastrointestinal tract.

2. A *Lactobacillus casei* strain or a mutant or variant thereof, wherein the *Lactobacillus casei* strain is significantly immunomodulatory following oral consumption in humans.

3. A *Lactobacillus casei* strain selected from any of strains AH101, AH104, AH111, AH112 or AH113 or mutants or variants thereof.

4. *Lactobacillus casei* strain AH101 or a mutant or variant thereof.

5. *Lactobacillus casei* strain AH104 or a mutant or variant thereof.

6. *Lactobacillus casei* strain AH111 or a mutant or variant thereof.

7. *Lactobacillus casei* strain AH112 or a mutant or variant thereof.

8. *Lactobacillus casei* strain AH113 or a mutant or variant thereof.

9. A *Lactobacillus casei* strain as claimed in any preceding claim wherein the mutant is a genetically modified mutant.

10. A *Lactobacillus casei* strain as claimed in any preceding claim wherein the variant is a naturally occurring variant of *Lactobacillus casei*.

11. A biologically pure culture of a *Lactobacillus casei* strain selected from any of strains AH101, AH104, AH111, AH112 or AH113.
12. A *Lactobacillus casei* strain as claimed in any of claims 1 to 11 in the form of viable cells.

13. A *Lactobacillus casei* strain as claimed in any of claims 1 to 11 in the form of non-viable cells.

14. A *Lactobacillus casei* strain as claimed in any of claims 2 to 13 wherein the *Lactobacillus casei* is isolated from resected and washed human gastrointestinal tract.

15. A *Lactobacillus casei* strain as claimed in any of claims 1 to 14 wherein the strain is capable of stimulating IL-10 production by PBMCs.

16. A *Lactobacillus casei* strain as claimed in claim 15 which is AH113.

17. A formulation which comprises at least one of the *Lactobacillus casei* strains as claimed in any of claims 1 to 16.

18. A formulation as claimed in claim 17 which includes another probiotic material.

19. A formulation as claimed in any of claims 17 or 18 which includes a prebiotic material.

20. A formulation as claimed in any of claims 17 to 19 which includes an ingestable carrier.

21. A formulation as claimed in claim 20 wherein the ingestable carrier is a pharmaceutically acceptable carrier such as a capsule, tablet or powder.
22. A formulation as claimed in claim 20 or 21 wherein the ingestable carrier is a food product such as acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spreads, dressings or beverages.

23. A formulation as claimed in any of claims 17 to 22 which further comprises a protein and/or peptide, in particular proteins and/or peptides that are rich in glutamine/glutamate, a lipid, a carbohydrate, a vitamin, mineral and/or trace element.

24. A formulation as claimed in claims 17 to 23 wherein the \textit{Lactobacillus casei} strain is present in an amount of more than $10^6$ cfu per gram of delivery system.

25. A formulation as claimed in claims 17 to 24 which includes an adjuvant.

26. A formulation as claimed in claims 17 to 25 which includes a bacterial component.

27. A formulation as claimed in claims 17 to 26 which includes a drug entity.

28. A formulation as claimed in claims 17 to 27 which includes a biological compound.

29. A formulation as claimed in claims 17 to 28 for use in immunisation and vaccination protocols.

30. A \textit{Lactobacillus casei} strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in foodstuffs.

31. A \textit{Lactobacillus casei} strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use as a medicament.
32. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the prophylaxis and/or treatment of undesirable inflammatory activity.

33. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the prophylaxis and/or treatment of undesirable gastrointestinal inflammatory activity such as; inflammatory bowel disease such as Crohn's disease or ulcerative colitis; irritable bowel syndrome; pouchitis; or post infection colitis.

34. A *Lactobacillus casei* strain as claimed in claim 33 wherein the inflammatory activity is irritable bowel syndrome

35. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the prophylaxis and/or treatment of gastrointestinal cancer(s).

36. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the prophylaxis and/or treatment of systemic disease such as rheumatoid arthritis.

37. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the prophylaxis and/or treatment of autoimmune disorders due to undesirable inflammatory activity.

38. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the prophylaxis and/or treatment of cancer due to undesirable inflammatory activity.
39. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the prophylaxis of cancer.

40. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the prophylaxis and/or treatment of diarrhoeal disease due to undesirable inflammatory activity, such as *Clostridium difficile* associated diarrhoea, Rotavirus associated diarrhoea or post infective diarrhoea, or diarrhoeal disease due to an infectious agent, such as *E.coli*.

41. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the preparation of anti-inflammatory biotherapeutic agents for the prophylaxis and/or treatment of undesirable inflammatory activity.

42. A *Lactobacillus casei* strain as claimed in claim 41 wherein the strains act by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract.

43. A *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claims 17 to 29 for use in the preparation of anti-inflammatory biotherapeutic agents for reducing the levels of proinflammatory cytokines.

44. A *Lactobacillus casei* strain selected from any one of AH101, AH104, AH112 or AH113 for use in the preparation of anti-inflammatory biotherapeutic agents for modifying the levels of IFNg.

45. A *Lactobacillus casei* strain AH111 for use in the preparation of anti-inflammatory biotherapeutic agents for reducing the levels of IL-8.
46. Use of a *Lactobacillus casei* strain as an anti-infective probiotic strain.

47. Use of a *Lactobacillus casei* strain selected from any one of AH101, AH104, AH111, AH112 or AH113 as an anti-infective probiotic strain.

48. A method of treating or preventing undesirable inflammatory activity or inflammatory disease in a subject which comprises administering to the subject a *Lactobacillus casei* strain as claimed in any of claims 1 to 16 or a formulation as claimed in any of claim 17 to 29.

49. A method as claimed in claim 48 wherein the undesirable inflammatory activity is gastrointestinal activity.

50. A method as claimed in claim 48 wherein the undesirable inflammatory activity is inflammatory bowel disease such as Crohn's disease or ulcerative colitis; irritable bowel syndrome; pouchitis; or post infection colitis.

51. A method as claimed in claim 48 wherein the undesirable inflammatory activity is irritable bowel syndrome.

52. A method of treating or preventing cancer in a subject which comprises administering to the subject a strain of *Lactobacillus casei* as claimed in any of claims 1 to 16 or a formulation as claimed in any of claim 17 to 29.

53. A method as claimed in claim 52 wherein the cancer is gastrointestinal cancer or cancer due to inflammation.

54. A method of treating or preventing a systemic disease associated with inflammation in a subject comprising administering to the subject a strain of a *Lactobacillus casei* as claimed in any of claims 1 to 16 or a formulation as claimed in any of claim 17 to 29.
55. A method as claimed in claim 54 wherein the systemic disease is rheumatoid arthritis.

56. A method of treating or preventing an autoimmune disorder caused by inflammation in a subject comprising administering to the subject a strain of Lactobacillus casei as claimed in any of claims 1 to 16 or a formulation as claimed in any of claim 17 to 29.

57. A method of treating or preventing a diarrhoeal disease in a subject comprising administering to the subject a strain of Lactobacillus casei as claimed in any of claims 1 to 16 or a formulation as claimed in any of claim 17 to 29.

58. A method as claimed in claim 57 wherein the diarrhoeal disease is Clostridium difficile associated diarrhoea, Rotavirus associated diarrhoea, post infective diarrhoea or diarrhoeal disease due to an infectious agent such as E. coli.
Fig. 1.

Fig. 2.
Fig. 5

Fig. 6
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N1/20 A61K35/74 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 98 35014 A (SULLIVAN GERALD CHRISTOPHER O.; THORNTON GERARDINE MARY (IE); UNIV) 13 August 1998 (1998-08-13) page 16, line 8 – page 17, line 30; examples 1-4; tables 2-5</td>
<td>1-58</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:
  - "*" document defining the general state of the art which is not considered to be of particular relevance
  - "*" earlier document but published on or after the international filing date
  - "L" document which may throw double on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O" document referring to an oral disclosure, use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search: 11 September 2002

Date of mailing of the international search report: 30/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx: 31 651 epo nl, Fax: (+31-70) 340-3016

Form PCT/ISA/210 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>EP 0 904 784 A (NUTRICIA NV) 31 March 1999 (1999-03-31) column 3, paragraph 1 -column 9, paragraph 3; claims</td>
<td>1-10, 12-14, 17-42, 46-58</td>
</tr>
<tr>
<td>X</td>
<td>WO 01 37865 A (CLANCY ROBERT LLEWELLYN; PANG GERALD (AU); PROBIALL PTY LTD (AU)) 31 May 2001 (2001-05-31) claims; example 1</td>
<td>1-31,37, 42-47,56</td>
</tr>
<tr>
<td>X</td>
<td>CHARTERIS W P ET AL: &quot;Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract&quot; JOURNAL OF APPLIED MICROBIOLOGY, OXFORD, GB, vol. 84, no. 5, May 1998 (1998-05), pages 759-768, XP000929203 ISSN: 1364-5072 abstract; table 1 page 760, right-hand column, paragraph 2 -page 761, left-hand column, paragraph 1</td>
<td>1-10, 12-14, 17-31,46</td>
</tr>
<tr>
<td>X</td>
<td>US 4 347 240 A (MUTAI MASAHIKO ET AL) 31 August 1982 (1982-08-31) the whole document</td>
<td>1-10, 12-14, 17-31, 35,38, 39,46, 52,53</td>
</tr>
<tr>
<td>E</td>
<td>WO 02 058712 A (PROBIO HEALTH ;NAIDU A SATYANARAYAN (US)) 1 August 2002 (2002-08-01) claims</td>
<td>1-10,12, 13, 17-31, 40,42, 46,57,58</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☑ Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
   Although claims 48-58 are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☑ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1999)
This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 9, 10, 12, 13, 15, 17-43 and 48-58 (partially); 1 (completely)

   a Lactobacillus casei strain or a mutant and or variant thereof isolated from resected and washed human gastrointestinal tract and subject-matter related thereto,

   i.e. a genetically modified mutant; a naturally occurring variant; said strain in the form of viable or non-viable cells; said strain which is capable of stimulating IL-10 production by PBMCs; a formulation comprising at least one of said strains and optionally another probiotic or prebiotic material, an ingestable carrier, a pharmaceutically acceptable carrier, a food product or a protein or peptide; said formulation wherein said strain is present in more than 10^6 cfu/g; said formulation which includes an adjuvant, a bacterial component, a drug entity or a biological compound; said formulation for use in immunisation and vaccination protocols; said strain or said formulation for use in foodstuffs, as a medicament or in the prophylaxis and/or treatment of undesirable inflammatory activity, gastrointestinal cancers, systemic disease such as rheumatoid arthritis, autoimmune disorders, cancer or diarrhoeal disease; said strain or said formulation for use in the preparation of antiinflammatory biotherapeutic agents or biotherapeutic agents for reducing the levels of pro-inflammatory cytokines; said strain acting by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract; methods of treating or preventing diseases related to an undesirable inflammatory activity, cancer or a diarrhoeal disease in a subject;

2. Claims: 9, 10, 12-15, 17-43 and 48-58 (partially); 2 (completely)

   a Lactobacillus casei strain or a mutant and or variant thereof being significantly immunomodulatory following oral consumption in humans and subject-matter related thereto,

   i.e. a genetically modified mutant; a naturally occurring variant; said strain in the form of viable or non-viable cells; said strain which is isolated from resected and washed human gastrointestinal tract or capable of stimulating IL-10 production by PBMCs; a formulation comprising at least one of said strains and optionally another probiotic or prebiotic material, an ingestable carrier, a pharmaceutically acceptable carrier, a food product or a protein or peptide; said formulation wherein said strain is present in more than 10^6 cfu/g; said
formulation which includes an adjuvant, a bacterial component, a drug entity or a biological compound; said formulation for use in immunisation and vaccination protocols; said strain or said formulation for use in foodstuffs, as a medicament or in the prophylaxis and/or treatment of undesirable inflammatory activity, gastrointestinal cancers, systemic disease such as rheumatoid arthritis, autoimmune disorders, cancer or diarrhoeal disease; said strain or said formulation for use in the preparation of antiinflammatory biotherapeutic agents or biotherapeutic agents for reducing the levels of pro-inflammatory cytokines; said strain acting by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract; methods of treating or preventing diseases related to an undesirable inflammatory activity, cancer or a diarrhoeal disease in a subject;

3. Claims: 3, 9-15, 17-44 and 47-58 (partially); 4 (completely)

Lactobacillus casei strain AH101 (NCIMB 41043), mutants and variants thereof and subject-matter related thereto,

i.e. a genetically modified mutant; a naturally occurring variant; a biologically pure culture; said strain in the form of viable or non-viable cells; said strain which is isolated from resected and washed human gastrointestinal tract or capable of stimulating IL-10 production by PBMCs; a formulation comprising at least one of said strains and optionally another probiotic or prebiotic material, an ingestable carrier, a pharmaceutically acceptable carrier, a food product or a protein or peptide; said formulation wherein said strain is present in more than 10^6 cfu/g; said formulation which includes an adjuvant, a bacterial component, a drug entity or a biological compound; said formulation for use in immunisation and vaccination protocols; said strain or said formulation for use in foodstuffs, as a medicament or in the prophylaxis and/or treatment of undesirable inflammatory activity, gastrointestinal cancers, systemic disease such as rheumatoid arthritis, autoimmune disorders, cancer or diarrhoeal disease; said strain or said formulation for use in the preparation of antiinflammatory biotherapeutic agents or biotherapeutic agents for reducing the levels of pro-inflammatory cytokines or modifying the levels of INFgamma; said strain acting by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract; use of AH101 as an anti-infective probiotic strain; methods of treating or preventing diseases related to an undesirable inflammatory activity, cancer or a diarrhoeal disease in a subject;
4. Claims: 3, 9-15, 17-44 and 47-58 (partially); 5 (completely)

Lactobacillus casei strain AH104 (NCIMB 41046), mutants and variants thereof and subject-matter related thereto,

i.e. a genetically modified mutant; a naturally occurring variant; a biologically pure culture; said strain in the form of viable or non-viable cells; said strain which is isolated from resected and washed human gastrointestinal tract or capable of stimulating IL-10 production by PBMCs; a formulation comprising at least one of said strains and optionally another probiotic or prebiotic material, an ingestable carrier, a pharmaceutically acceptable carrier, a food product or a protein or peptide; said formulation wherein said strain is present in more than 10^6 cfu/g; said formulation which includes an adjuvant, a bacterial component, a drug entity or a biological compound; said formulation for use in immunisation and vaccination protocols; said strain or said formulation for use in foodstuffs, as a medicament or in the prophylaxis and/or treatment of undesirable inflammatory activity, gastrointestinal cancers, systemic disease such as rheumatoid arthritis, autoimmune disorders, cancer or diarrhoeal disease; said strain or said formulation for use in the preparation of antiinflammatory biotherapeutic agents or biotherapeutic agents for reducing the levels of pro-inflammatory cytokines or modifying the levels of INFgamma; said strain acting by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract; use of AH104 as an anti-infective probiotic strain; methods of treating or preventing diseases related to an undesirable inflammatory activity, cancer or a diarrhoeal disease in a subject;

5. Claims: 3, 9-15, 17-43 and 47-58 (partially); 6 and 45 (completely)

Lactobacillus casei strain AH111 (NCIMB 41095), mutants and variants thereof and subject-matter related thereto,

i.e. a genetically modified mutant; a naturally occurring variant; a biologically pure culture; said strain in the form of viable or non-viable cells; said strain which is isolated from resected and washed human gastrointestinal tract or capable of stimulating IL-10 production by PBMCs; a formulation comprising at least one of said strains and optionally another probiotic or prebiotic material, an ingestable carrier, a pharmaceutically acceptable carrier, a food product or a protein or peptide; said formulation wherein said strain is present in more than 10^6 cfu/g; said formulation which includes an adjuvant, a bacterial
component, a drug entity or a biological compound; said formulation for use in immunisation and vaccination protocols; said strain or said formulation for use in foodstuffs, as a medicament or in the prophylaxis and/or treatment of undesirable inflammatory activity, gastrointestinal cancers, systemic disease such as rheumatoid arthritis, autoimmune disorders, cancer or diarrhoeal disease; said strain or said formulation for use in the preparation of antiinflammatory biotherapeutic agents or biotherapeutic agents for reducing the levels of pro-inflammatory cytokines or reducing the levels of IL-8; said strain acting by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract; use of AH111 as an anti-infective probiotic strain; methods of treating or preventing diseases related to an undesirable inflammatory activity, cancer or a diarrhoeal disease in a subject;

6. Claims: 3, 9-15, 17-44 and 47-58 (partially); 7 (completely)

Lactobacillus casei strain AH112 (NCIMB 41096), mutants and variants thereof and subject-matter related thereto, i.e. a genetically modified mutant; a naturally occurring variant; a biologically pure culture; said strain in the form of viable or non-viable cells; said strain which is isolated from resected and washed human gastrointestinal tract or capable of stimulating IL-10 production by PBMCs; a formulation comprising at least one of said strains and optionally another probiotic or prebiotic material, an ingestable carrier, a pharmaceutically acceptable carrier, a food product or a protein or peptide; said formulation wherein said strain is present in more than 10^6 cfu/g; said formulation which includes an adjuvant, a bacterial component, a drug entity or a biological compound; said formulation for use in immunisation and vaccination protocols; said strain or said formulation for use in foodstuffs, as a medicament or in the prophylaxis and/or treatment of undesirable inflammatory activity, gastrointestinal cancers, systemic disease such as rheumatoid arthritis, autoimmune disorders, cancer or diarrhoeal disease; said strain or said formulation for use in the preparation of antiinflammatory biotherapeutic agents or biotherapeutic agents for reducing the levels of pro-inflammatory cytokines or modifying the levels of INFgamma; said strain acting by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract; use of AH112 as an anti-infective probiotic strain; methods of treating or preventing diseases related to an undesirable inflammatory activity, cancer or a diarrhoeal disease in a subject;
7. Claims: 3, 9-15, 17-44 and 47-58 (partially); 8 and 16 (completely)

Lactobacillus casei strain AH113 (NCIMB 41097), mutants and variants thereof and subject-matter related thereto,

1.e. a genetically modified mutant; a naturally occurring variant; a biologically pure culture; said strain in the form of viable or non-viable cells; said strain which is isolated from resected and washed human gastrointestinal tract or capable of stimulating IL-10 production by PBMCs; a formulation comprising at least one of said strains and optionally another probiotic or prebiotic material, an ingestable carrier, a pharmaceutically acceptable carrier, a food product or a protein or peptide; said formulation wherein said strain is present in more than 10^6 cfu/g; said formulation which includes an adjuvant, a bacterial component, a drug entity or a biological compound; said formulation for use in immunisation and vaccination protocols; said strain or said formulation for use in foodstuffs, as a medicament or in the prophylaxis and/or treatment of undesirable inflammatory activity, gastrointestinal cancers, systemic disease such as rheumatoid arthritis, autoimmune disorders, cancer or diarrhoeal disease; said strain or said formulation for use in the preparation of antiinflammatory biotherapeutic agents or biotherapeutic agents for reducing the levels of pro-inflammatory cytokines or modifying the levels of INFgamma; said strain acting by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract; use of AH113 as an anti-infective probiotic strain; methods of treating or preventing diseases related to an undesirable inflammatory activity, cancer or a diarrhoeal disease in a subject;

8. Claim: 46 (completely);

use of a Lactobacillus casei strain as an anti-infective probiotic strain;
### INTERNATIONAL SEARCH REPORT

#### Information on patent family members

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>EP 1002051 A2</td>
<td>24-05-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9835014 A2</td>
<td>13-08-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002514068 T</td>
<td>14-05-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 993818 A</td>
<td>11-10-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 337505 A</td>
<td>27-07-2001</td>
</tr>
</tbody>
</table>


|                                       |                 | AU 1373401 A           | 04-06-2001      |
|                                       |                 | BR 0015698 A           | 23-07-2002      |
|                                       |                 | EP 1229930 A1          | 14-08-2002      |

|                                       |                 | JP 55113718 A         | 02-09-1980      |
|                                       |                 | JP 62034727 B         | 28-07-1987      |
|                                       |                 | BR 8001129 A          | 04-11-1980      |
|                                       |                 | CA 1124176 A1         | 25-05-1982      |
|                                       |                 | CH 653556 A5          | 15-01-1986      |
|                                       |                 | DE 3007412 A1         | 06-11-1980      |
|                                       |                 | FR 2450108 A1         | 26-09-1980      |
|                                       |                 | HK 23784 A            | 23-03-1984      |
|                                       |                 | IT 1129802 B          | 11-06-1986      |
|                                       |                 | MX 6031 E             | 03-10-1984      |
|                                       |                 | MY 1085 A             | 31-12-1985      |
|                                       |                 | NL 8001045 A, B,      | 29-08-1980      |
|                                       |                 | SG 38183 G            | 20-07-1984      |

| WO 02058712                           | 01-08-2002      | WO 02058712 A2         | 01-08-2002      |